Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $16.70

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $16.70.

Several analysts have recently issued reports on the stock. Wedbush lifted their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a research report on Monday, June 30th. Bank of America lifted their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, July 1st. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC grew its holdings in BioCryst Pharmaceuticals by 68.1% in the 4th quarter. Lazard Asset Management LLC now owns 161,516 shares of the biotechnology company’s stock valued at $1,214,000 after buying an additional 65,420 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $80,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at about $79,000. Jupiter Asset Management Ltd. increased its position in BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock worth $16,117,000 after purchasing an additional 971,040 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in BioCryst Pharmaceuticals by 3.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock worth $3,016,000 after purchasing an additional 11,581 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 2.2%

Shares of BCRX opened at $8.53 on Monday. The firm has a market cap of $1.79 billion, a P/E ratio of -47.39, a PEG ratio of 1.90 and a beta of 1.10. BioCryst Pharmaceuticals has a 12 month low of $6.01 and a 12 month high of $11.31. The stock’s 50 day moving average is $9.16 and its two-hundred day moving average is $8.77.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to analysts’ expectations of $149.59 million. The company’s quarterly revenue was up 49.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) EPS. Equities research analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.